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lecting meaningful and responsive quality of life instru-
ments for use in clinical trials and other evaluative studies.
Health outcomes and quality of life assessment is becom-
ing increasingly important in the evaluation of pharma-
ceutical products, in terms of labeling claims and product
promotion as well as in terms of formulary decisions.
Each of these uses requires an assessment strategy that
provides information relevant for decision-making. What
are the components of a successful strategy? How is a
given strategy evaluated to select the best for the given
evaluative study? This workshop will address these ques-
tions and introduce an analytic framework that partici-
pants can apply in their daily experience.
SESSION 3
WPE7
SCHIZOPHRENIA: HELPING THE DECISION-
MAKER TO UNDERSTAND THE IMPACTS OF 
ATYPICAL ANTIPSYCHOTICS
Mauskopf J1, David K1, Muroff M1, Grainger D2, Gibson PJ2
1Research Triangle Institute, Research Triangle Park, NC, USA; 
2Eli Lilly & Company, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to demonstrate, using a schizophrenia case study,
how prevalence-based drug value information can be pre-
sented in a format that is understandable and useful for
decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to learn a process that will increase the likelihood
that prevalence-based drug value analyses are used by de-
cision-makers.
Although many drug value analyses have been completed
in recent years, it is not clear to what extent these analy-
ses have been used to inform decisions. In a recent paper,
Mauskopf (VH 1998) has suggested that prevalence-
based annual estimates of population and cost outcomes
would be of value to decision-makers. In this workshop,
we will take the participants through a series of activities
designed to ensure that decision-makers can understand
and use the results of prevalence-based drug value analy-
ses. We will illustrate these activities using a project that
we recently completed for schizophrenia. In this project,
we developed an interactive computer model to estimate
the impacts of the atypical anti-psychotics on patient and
family outcomes and healthcare costs for a population of
schizophrenia patients. The project included three main
activities: 1) develop a preliminary model; 2) present the
model to decision-makes to determine its value to them;
and 3) revise the model based on decision-maker com-
ments and create an interactive computer version of the
model. We will show the workshop participants how we
presented our model to the decision-makers. We will
summarize the decision-makers responses to the presen-
tation. We will then lead the workshop participants in a
discussion about the range of possible responses to these
comments and the trade-offs between 1) keeping a model
well grounded in published literature; and 2) extrapolating
information to address outcomes that are important to de-
cision-makers, but not well researched. We will conclude
the workshop by describing how we modified the prelimi-
nary model in response to the decision-makers’ comments
and by showing the final interactive computer model.
WPE8
DESIGNING NATURALISTIC OUTCOMES 
TRIALS THAT ARE APPLICABLE TO THE “REAL 
WORLD” OF CLINICAL PRACTICE
Tunis SL, Melfi CA, Robinson R
Eli Lilly and Company, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: To highlight design features
that characterize state-of-the-art studies evaluating out-
comes of competing pharmacotherapies, balancing the need
to maintain internal validity with the goal of providing in-
formation that can be applied to the “real world” of clinical
practices.
PARTICIPANTS WHO WOULD BENEFIT: 1) Out-
comes researchers, statisticians, health economists, and
others who wish to expand beyond the traditional clini-
cal trial design; and 2) clinicians, healthcare organiza-
tions, and others who wish to learn more about how to
make informed decisions based on comparative cost and
effectiveness claims.
Various methodological issues are critical in the design of
naturalistic outcomes trials. These include how narrowly
(or broadly) to define the patient population, whether or
not to “blind” the study, how much physician discretion
to allow in treating patients, and how to obtain and ana-
lyze data on patients who switch from their originally-as-
signed medication (or on patients who discontinue medi-
cation). Additionally, the definition of comparator(s) and
the appropriate time horizon of the study are important.
These and other issues will be discussed and illustrated
through examples of two randomized naturalistic trials de-
signed by the workshop leaders and colleagues. One study
is designed to answer the question of whether using an
atypical antipsychotic agent as first-line therapy is more ef-
fective and less costly than requiring a patient to first fail
on conventional medications. The other study is designed
to determine how three different selective serotonin re-
uptake inhibitors compare in terms of various outcome
measures including patient adherence, quality of life, and
resource utilization. The authors will discuss the decisions
made in designing these trials and the implications of these
decisions for data analysis and interpretation of findings.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to review guidelines in current use and under
development to determine similarities, emerging trends
and the implications for the use and development of
guidelines in the future.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to develop an understanding of the guidelines pro-
cess and the means of establishing appropriate study de-
sign criteria to apply in international pharmacoeconomic
studies in order to meet the requirements of as many
guidelines as possible.
Guidelines for the economic evaluation of pharmaceuticals
are being developed around the world by academia, indus-
try, government, payers and external consultants. These
guidelines can be categorized according to their main pur-
pose: methods guidelines; guidelines for formulary submis-
sions; principles of conduct; and substantiation of evidence
for promotional claims. Review of the guidelines reveals a
number of common themes which will allow some com-
parison of studies across countries. Differences outside
these common themes may be attributable to particular
differences in the settings in which individual guidelines
are applicable. However, what is most noticeable is the
trends emerging from what appears to be a flourishing
field of guidelines development. Methodological trends are
evident in study design (with greater acceptance of model-
ling studies), valuation of health outcomes and productiv-
ity changes (indirect costs). In addition, the formal require-
ment for economic evaluation of pharmaceuticals is being
extended into more countries and we can expect to see
pharmacoeconomic guidelines being increasingly used. If
this encourages cost-effective prescribing then the ultimate
impact will be in providing benefit to patients.
WTG2
UPDATE ON THE SCRIPT PROJECT
Westrick E
Rhode Island Quality Partners, Providence, RI, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to update participants on the progress of the
SCRIPT project.
PARTICIPANTS WHO WOULD BENEFIT: Stakehold-
ers in medication use quality would benefit by participat-
ing in this workshop.
Background for the SCRIPT project was presented at last
year’s meeting of ISPOR in Philadelphia. Since that time,
there has been significant progress. The SCRIPT project is
the first concerted effort of the Coalition for Quality in
Medication Use. The purpose of the project is to create a
method for consensus-based quality indicator development
and a compendium of core indicators measuring quality in
medication use that will be recommended for implementa-
tion by coalition members. The Coalition for Quality in
Medication Use currently includes about 50 national orga-
nizations. The SCRIPT project is funded by HCFA, and
staffed by JCAHO. Daily management is provided by a
Steering Committee composed of representatives from
AAHP, AHCPR, AHQA, AMA, APhA, HCFA, JCAHO,
NCQA, and two science advisors. The coalition met for the
first time in July 1998. A Call for Measures has gone out
and existing compendia of measures have been collected.
Criteria for evaluating measures are in development and a
technical expert panel is being formed to evaluate the mea-
sures in a cluster of clinical conditions with high disease
burden and significant quality issues in medication use.
Clinical conditions, medication use issues, and some of the
considered measures will be identified at this workshop. Ad-
ditional progress in this area will be shared in the workshop
as well as preliminary plans to test candidate measures.
WTG5
EVALUATION OF FORMULARY DECISIONS: 
PROJECTED IMPACT OF A NEW DRUG 
ROLLOUT WITHIN THE MANAGED CARE 
ARENA
Wright A, Wolff J
Advance Paradigm, Inc., Hunt Valley, MD, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to demonstrate the nature of decision-making
tools employed within the managed care industry to evalu-
ate pharmacy-related issues. This workshop will use an
economic model to demonstrate the type of logic used by
MCOs to project pharmacy costs and to evaluate the im-
pact of formulary changes. Participants will learn how to
utilize pharmacy and medical administrative claims data
to assess the potential increase in pharmacy costs associ-
ated with the introduction of new drugs and/or treatments.
PARTICIPANTS WHO WOULD BENEFIT: Managed
care decision-makers, pharmacy directors, and health econ-
omists who are involved in the evaluation of pharmacy
costs and business issues related to formulary changes.
Rising pharmaceutical expenditures in recent years have
led to increased scrutiny of this benefit among healthcare
insurers in the United States. Managed care organizations
(MCOs) are increasingly questioning available options with
regard to the introduction of new classes of prescription
drugs and other new therapies. Economic models are an im-
portant vehicle that may be utilized by decision-makers to
better understand the financial implications of formulary
changes. We will discuss a model recently developed to
simulate the impact of prescription Cox-2 inhibitor medi-
cations on pharmacy costs of a managed care health plan.
This session will explain the assumptions made, data used,
and processes employed in the development of this eco-
nomic model.
WDM3
APPLYING PRACTICAL APPLICATIONS OF 
PHARMACOECONOMICS AND OUTCOMES 
DATA IN THE COMMUNITY 
HEALTHCARE FACILITY
Santorello JG
John T. Mather Memorial Hospital, Port Jefferson, NY, USA
